• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Oragenics Inc (NY: OGEN )

    0.3474 -0.0166 (-4.56%)
    Streaming Delayed Price Updated: 11:36 AM EST, Nov 13, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 126,295
    Open 0.3648
    Bid (Size) 0.3429 (3)
    Ask (Size) 0.3515 (3)
    Prev. Close 0.3640
    Today's Range 0.3400 - 0.3694
    52wk Range 0.2800 - 7.740
    Shares Outstanding 5,580,693
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why Grab Holdings Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Oragenics to Present at Centurion One Capital 2nd Annual Bahamas Summit
    Via Investor Brand Network

    Performance

    YTD
    -94.88%
    -94.88%
    1 Month
    +10.22%
    +10.22%
    3 Month
    -84.42%
    -84.42%
    6 Month
    -78.95%
    -78.95%
    1 Year
    -90.46%
    -90.46%

    More News

    Read More
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    BioMedNewsBreaks — Oragenics, Inc. (NYSE American: OGEN) Reports on Lead Candidate Drug Development, ‘Urgency’ to Advance First-in-Class Concussion Treatment
    Via Investor Brand Network
    Exposures Product Safety
    Why Oragenics (OGEN) Stock Is Getting Hammered
    Via Benzinga
    OGEN Stock Earnings: Oragenics Reported Results for Q2 2024
    Via InvestorPlace
    OGEN Stock Earnings: Oragenics Reported Results for Q4 2023
    Via InvestorPlace
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Advances Concussion Treatment with Promising Study for Nasal Spray Drug ONP-002
    Via Investor Brand Network
    EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate
    Via Benzinga
    Why DocuSign Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Why Oragenics (OGEN) Shares Are Falling
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Closes on $4.45M Public Offering
    Via Investor Brand Network
    BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Enters into Public Offering Agreement Estimated to Total $4.45M
    Via Investor Brand Network
    Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings
    Via Benzinga
    Exposures Fossil Fuels
    US Stocks Mixed; Trade Gap Widens In July
    Via Benzinga
    Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Completes Manufacture, Filling of Intranasal Device for Use in Upcoming Clinical Trial
    Via Investor Brand Network
    EXCLUSIVE: Oragenics Completes Spray Dry Drug Manufacturing, Intranasal Device Filling For Anticipated Mid-Stage Study For Patients With Brain Injury
    Via Benzinga
    BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Reports on Status of Lead Drug Candidate Designed to Treat Concussion
    Via Investor Brand Network
    Exposures Product Safety
    “Explosive Growth Stocks: Innovations, Strategy, Earners Unlock Prime Potential CXAI, OGEN, PRSO, INBS, KAVL”
    Via AB Newswire
    Topics Artificial Intelligence
    Exposures Artificial Intelligence Product Safety
    As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
    Via FinancialNewsMedia
    EXCLUSIVE: Oragenics' Concussion Drug Clears FDA-Required Cardiotoxicity Testing, Planning For Phase Trials Underway
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.